DODC

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
DODC
File:DODC.svg
Identifiers
  • 1-(2,5-dimethoxy-3,4-dichlorophenyl)propan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
E number{{#property:P628}}
CompTox Dashboard (EPA)
  • {{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC11H15Cl2NO2
Molar mass264.15 g·mol−1
3D model (JSmol)
  • Clc1c(OC)cc(CC(C)N)c(OC)c1Cl
  • InChI=1S/C11H15Cl2NO2/c1-6(14)4-7-5-8(15-2)9(12)10(13)11(7)16-3/h5-6H,4,14H2,1-3H3
  • Key:IGOFLAWWDQNRCV-UHFFFAOYSA-N

DODC is a psychedelic drug from the substituted amphetamine family which acts as an agonist of the 5-HT2A receptor. It is the 3,4-dichloro derivative of the well known psychedelic drug 2,5-dimethoxy-4-chloroamphetamine (DOC). DODC was first officially published in a patent filed by Gilgamesh Pharmaceuticals in 2020,[1] though anecdotal reports suggest it had been synthesised by clandestine chemists and its activity established several years prior to this.

See also

[edit | edit source]

References

[edit | edit source]
  1. ^ WO 2022/006186, Kruegel AC, "Phenalkylamines and Methods of Treating Mood Disorders.", published Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value)., assigned to Gilgamesh Pharmaceuticals.